Research conducted by MJ Biologics and the University of Minnesota has led to the decoding of the PRRS virus and the development of a new inactivated subunit vaccine according to a recent press release.
The company reports that the new technology allows the production of autogenous vaccines that are tailored to each unique swine production system. This technology utilizes an innovative method of classifying PRRS viruses based on their immunological properties, allowing for the creation of new custom vaccines as a tool against intra-farm mutations. In addition, the enhanced cross-protection capability helps to reduce financial losses from new strains introduced into the farm.
For more information on MJPRRS vaccine, contact MJ Biologics at (507) 385-0299 or visit http://www.mjbio.com.
Source: MJ Biologics Press Release, May 23, 2008